1. Defective natural killer cell anti-viral capacity in paediatric HBV infection. (16th February 2015) Authors: Heiberg, I L; Pallett, L J; Winther, T N; Høgh, B; Maini, M K; Peppa, D Journal: Clinical and experimental immunology Issue: Volume 179:Number 3(2015:Mar.) Page Start: 466 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Pegylated interferon α modulates innate immunity in eAg positive chronic hepatitis B and determines changes in HBsAg quantification. (13th March 2011) Authors: Gill, U; Micco, L; Li, L; Peppa, D; Ushiro-Lumb, I; Foster, G R; Maini, M K; Kennedy, P T F Journal: Gut Issue: Volume 60:(2011)Supplement 1 Page Start: A232 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. PMO-177 Maximal boosting of innate immunity during pegylated interferon-α therapy is reached at 48 weeks in e-antigen positive chronic hepatitis B. (28th May 2012) Authors: Gill, U S; Papadaki, M; Peppa, D; Micco, L; Li, L; Ushiro-Lumb, I; Foster, G R; Maini, M K; Kennedy, P T F Journal: Gut Issue: Volume 61(2012)Supplement 2 Page Start: A145 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PTU-116 Functional immune restoration correlates with HBSAG decline and may predict treatment response on sequential NUC therapy in CHB. (22nd June 2015) Authors: Gill, US; Peppa, D; Micco, L; Singh, HD; Foster, GR; Maini, MK; Kennedy, PTF Journal: Gut Issue: Volume 64(2015)Supplement 1 Page Start: A113 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗